Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1993]

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )

CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory...

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

$CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )$

CANDOR updated results: KdD versus Kd in patients with RRMM according to prior...

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

CANDOR updated results: KdD versus Kd in patients with RRMM according to prior lines of therapy ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )

Patient reported outcomes for the CANDOR trial for multiple myeloma

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

Patient reported outcomes for the CANDOR trial for multiple myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )

FORTE trial: Minimal residual disease evaluation in newly diagnosed multiple...

Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy

FORTE trial: Minimal residual disease evaluation in newly diagnosed multiple myeloma ( Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy )

Comparing pevonedistat plus azacitidine versus azacitidine alone in patients...

Prof Lionel Ades - Hôpital Saint-Louis, Paris, France

Comparing pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk MDS/CMML or low-blast AML ( Prof Lionel Ades - Hôpital Saint-Louis, Paris, France )

Timing of response to venetoclax combination treatment in older patients with...

Dr Brian Jonas - University of California Davis Comprehensive Cancer Center...

Timing of response to venetoclax combination treatment in older patients with acute myeloid leukaemia ( Dr Brian Jonas - University of California Davis Comprehensive Cancer Center, Sacramento, USA )

Venetoclax with bortezomib and dexamethasone in relapsed/refractory multiple...

Dr Shaji Kumar - Mayo Clinic, Rochester, USA

$Venetoclax with bortezomib and dexamethasone in relapsed/refractory multiple myeloma ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )$

KRd vs VRd for initial therapy of newly diagnosed multiple myeloma

Dr Shaji Kumar - Mayo Clinic, Rochester, USA

KRd vs VRd for initial therapy of newly diagnosed multiple myeloma ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )

Teclistamab for patients with heavily pretreated relapsed or refractory...

Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA

$Teclistamab for patients with heavily pretreated relapsed or refractory multiple myeloma ( Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA )$

Denosumab in multiple myeloma patients with renal insufficiency

Dr Elizabeth O'Donnell - Massachusetts General Hospital, Boston, USA

Denosumab in multiple myeloma patients with renal insufficiency ( Dr Elizabeth O'Donnell - Massachusetts General Hospital, Boston, USA )

CARTITUDE-1: JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell...

Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA

CARTITUDE-1: JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy for r/r multiple myeloma ( Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA )

More from ecancer